Learn about the latest developments in the pharmaceutical cannabis industry with Business of Cannabis. Discover new drugs, research, and more.
Brains Bioceutical Corp. has announced plans to list on Nasdaq, in what would be the first US public-market debut for a UK-based cannabinoid pharma manufacturer since GW Pharmaceuticals was acquired by Jazz in 2021.
James Duckenfield, CEO of Glass Pharms®, explains why we may be underestimating the pharmaceutical potential of cannabis, and how research, formulation and more controlled delivery could help realise it.
Irish pharmaceutical cannabis manufacturer Dunbar Pharmaceuticals has today launched the first plant-derived dronabinol active ingredient into the UK market.
Argent Biopharma’s (RGT) flagship CannEpil cannabis drug is set to pivot into the veterinary market, just weeks after it signed away the commercial rights in exchange for debt relief.
Ananda Pharma has dosed the first patient in the ACTiON trial, a Phase 2 NIHR-funded study evaluating MRX1, the company’s proprietary CBD-based oral solution, as a treatment for chemotherapy-induced peripheral neuropathy (CIPN), a debilitating nerve-damage condition caused by chemotherapy for which no effective therapies currently exist.
The world’s largest clinical trial on cannabidiol (CBD) as a treatment for insomnia has been given the green light to complete its Phase III trial, transforming the fortunes of Avecho Biotechnology, and potentially the lives of insomnia sufferers worldwide.
This week, what is perhaps the most consequential hearing in the history of the US, and indeed the global cannabis industry, is taking place in Arlington, Virginia.
Cultivation is perhaps the most complex, highly regulated, and expensive part of the cannabis supply chain.
Ananda Pharma has taken another major step forward in bringing its flagship MRX1 CBD oral solution to market.
